Global Mucopolysaccharidosis Therapeutics Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).
LPI (LP Information)' newest research report, the “Mucopolysaccharidosis Therapeutics Industry Forecast” looks at past sales and reviews total world Mucopolysaccharidosis Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Mucopolysaccharidosis Therapeutics sales for 2023 through 2029. With Mucopolysaccharidosis Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mucopolysaccharidosis Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Mucopolysaccharidosis Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mucopolysaccharidosis Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mucopolysaccharidosis Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mucopolysaccharidosis Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mucopolysaccharidosis Therapeutics.
The global Mucopolysaccharidosis Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Mucopolysaccharidosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Mucopolysaccharidosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Mucopolysaccharidosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Mucopolysaccharidosis Therapeutics players cover Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc. and Ultragenyx Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Mucopolysaccharidosis Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
MPS, also known as mucopolysaccharidosis, refers to a group of key rare metabolic disorders which is caused by the absence, deficiency or malfunctioning of lysosomal enzymes called glycosaminoglycan (GAGs).
LPI (LP Information)' newest research report, the “Mucopolysaccharidosis Therapeutics Industry Forecast” looks at past sales and reviews total world Mucopolysaccharidosis Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Mucopolysaccharidosis Therapeutics sales for 2023 through 2029. With Mucopolysaccharidosis Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mucopolysaccharidosis Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Mucopolysaccharidosis Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mucopolysaccharidosis Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mucopolysaccharidosis Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mucopolysaccharidosis Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mucopolysaccharidosis Therapeutics.
The global Mucopolysaccharidosis Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Mucopolysaccharidosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Mucopolysaccharidosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Mucopolysaccharidosis Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Mucopolysaccharidosis Therapeutics players cover Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc. and Ultragenyx Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Mucopolysaccharidosis Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Intravenous
- Intracerebroventricular (ICV)
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Shire (Takeda Pharmaceutical Company Limited)
- Denali Therapeutics
- ArmaGen
- REGENXBIO Inc.
- Sangamo Therapeutics
- BioMarin
- Lysogene
- Abeona Therapeutics Inc.
- Ultragenyx Pharmaceutical
- Genzyme Corporation
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Mucopolysaccharidosis Therapeutics Market Size 2018-2029
2.1.2 Mucopolysaccharidosis Therapeutics Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Mucopolysaccharidosis Therapeutics Segment by Type
2.2.1 Intravenous
2.2.2 Intracerebroventricular (ICV)
2.3 Mucopolysaccharidosis Therapeutics Market Size by Type
2.3.1 Mucopolysaccharidosis Therapeutics Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
2.4 Mucopolysaccharidosis Therapeutics Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Mucopolysaccharidosis Therapeutics Market Size by Application
2.5.1 Mucopolysaccharidosis Therapeutics Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
3 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Mucopolysaccharidosis Therapeutics Market Size Market Share by Players
3.1.1 Global Mucopolysaccharidosis Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Mucopolysaccharidosis Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MUCOPOLYSACCHARIDOSIS THERAPEUTICS BY REGIONS
4.1 Mucopolysaccharidosis Therapeutics Market Size by Regions (2018-2023)
4.2 Americas Mucopolysaccharidosis Therapeutics Market Size Growth (2018-2023)
4.3 APAC Mucopolysaccharidosis Therapeutics Market Size Growth (2018-2023)
4.4 Europe Mucopolysaccharidosis Therapeutics Market Size Growth (2018-2023)
4.5 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
5.2 Americas Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023)
5.3 Americas Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023)
6.2 APAC Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023)
6.3 APAC Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Mucopolysaccharidosis Therapeutics by Country (2018-2023)
7.2 Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023)
7.3 Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Mucopolysaccharidosis Therapeutics by Region (2018-2023)
8.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023)
8.3 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET FORECAST
10.1 Global Mucopolysaccharidosis Therapeutics Forecast by Regions (2024-2029)
10.1.1 Global Mucopolysaccharidosis Therapeutics Forecast by Regions (2024-2029)
10.1.2 Americas Mucopolysaccharidosis Therapeutics Forecast
10.1.3 APAC Mucopolysaccharidosis Therapeutics Forecast
10.1.4 Europe Mucopolysaccharidosis Therapeutics Forecast
10.1.5 Middle East & Africa Mucopolysaccharidosis Therapeutics Forecast
10.2 Americas Mucopolysaccharidosis Therapeutics Forecast by Country (2024-2029)
10.2.1 United States Mucopolysaccharidosis Therapeutics Market Forecast
10.2.2 Canada Mucopolysaccharidosis Therapeutics Market Forecast
10.2.3 Mexico Mucopolysaccharidosis Therapeutics Market Forecast
10.2.4 Brazil Mucopolysaccharidosis Therapeutics Market Forecast
10.3 APAC Mucopolysaccharidosis Therapeutics Forecast by Region (2024-2029)
10.3.1 China Mucopolysaccharidosis Therapeutics Market Forecast
10.3.2 Japan Mucopolysaccharidosis Therapeutics Market Forecast
10.3.3 Korea Mucopolysaccharidosis Therapeutics Market Forecast
10.3.4 Southeast Asia Mucopolysaccharidosis Therapeutics Market Forecast
10.3.5 India Mucopolysaccharidosis Therapeutics Market Forecast
10.3.6 Australia Mucopolysaccharidosis Therapeutics Market Forecast
10.4 Europe Mucopolysaccharidosis Therapeutics Forecast by Country (2024-2029)
10.4.1 Germany Mucopolysaccharidosis Therapeutics Market Forecast
10.4.2 France Mucopolysaccharidosis Therapeutics Market Forecast
10.4.3 UK Mucopolysaccharidosis Therapeutics Market Forecast
10.4.4 Italy Mucopolysaccharidosis Therapeutics Market Forecast
10.4.5 Russia Mucopolysaccharidosis Therapeutics Market Forecast
10.5 Middle East & Africa Mucopolysaccharidosis Therapeutics Forecast by Region (2024-2029)
10.5.1 Egypt Mucopolysaccharidosis Therapeutics Market Forecast
10.5.2 South Africa Mucopolysaccharidosis Therapeutics Market Forecast
10.5.3 Israel Mucopolysaccharidosis Therapeutics Market Forecast
10.5.4 Turkey Mucopolysaccharidosis Therapeutics Market Forecast
10.5.5 GCC Countries Mucopolysaccharidosis Therapeutics Market Forecast
10.6 Global Mucopolysaccharidosis Therapeutics Forecast by Type (2024-2029)
10.7 Global Mucopolysaccharidosis Therapeutics Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Shire (Takeda Pharmaceutical Company Limited)
11.1.1 Shire (Takeda Pharmaceutical Company Limited) Company Information
11.1.2 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Offered
11.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Shire (Takeda Pharmaceutical Company Limited) Main Business Overview
11.1.5 Shire (Takeda Pharmaceutical Company Limited) Latest Developments
11.2 Denali Therapeutics
11.2.1 Denali Therapeutics Company Information
11.2.2 Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Offered
11.2.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Denali Therapeutics Main Business Overview
11.2.5 Denali Therapeutics Latest Developments
11.3 ArmaGen
11.3.1 ArmaGen Company Information
11.3.2 ArmaGen Mucopolysaccharidosis Therapeutics Product Offered
11.3.3 ArmaGen Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 ArmaGen Main Business Overview
11.3.5 ArmaGen Latest Developments
11.4 REGENXBIO Inc.
11.4.1 REGENXBIO Inc. Company Information
11.4.2 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Offered
11.4.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 REGENXBIO Inc. Main Business Overview
11.4.5 REGENXBIO Inc. Latest Developments
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Information
11.5.2 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Offered
11.5.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Sangamo Therapeutics Main Business Overview
11.5.5 Sangamo Therapeutics Latest Developments
11.6 BioMarin
11.6.1 BioMarin Company Information
11.6.2 BioMarin Mucopolysaccharidosis Therapeutics Product Offered
11.6.3 BioMarin Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 BioMarin Main Business Overview
11.6.5 BioMarin Latest Developments
11.7 Lysogene
11.7.1 Lysogene Company Information
11.7.2 Lysogene Mucopolysaccharidosis Therapeutics Product Offered
11.7.3 Lysogene Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Lysogene Main Business Overview
11.7.5 Lysogene Latest Developments
11.8 Abeona Therapeutics Inc.
11.8.1 Abeona Therapeutics Inc. Company Information
11.8.2 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Offered
11.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Abeona Therapeutics Inc. Main Business Overview
11.8.5 Abeona Therapeutics Inc. Latest Developments
11.9 Ultragenyx Pharmaceutical
11.9.1 Ultragenyx Pharmaceutical Company Information
11.9.2 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Offered
11.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Ultragenyx Pharmaceutical Main Business Overview
11.9.5 Ultragenyx Pharmaceutical Latest Developments
11.10 Genzyme Corporation
11.10.1 Genzyme Corporation Company Information
11.10.2 Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Offered
11.10.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Genzyme Corporation Main Business Overview
11.10.5 Genzyme Corporation Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Mucopolysaccharidosis Therapeutics Market Size 2018-2029
2.1.2 Mucopolysaccharidosis Therapeutics Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Mucopolysaccharidosis Therapeutics Segment by Type
2.2.1 Intravenous
2.2.2 Intracerebroventricular (ICV)
2.3 Mucopolysaccharidosis Therapeutics Market Size by Type
2.3.1 Mucopolysaccharidosis Therapeutics Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
2.4 Mucopolysaccharidosis Therapeutics Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Mucopolysaccharidosis Therapeutics Market Size by Application
2.5.1 Mucopolysaccharidosis Therapeutics Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
3 MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Mucopolysaccharidosis Therapeutics Market Size Market Share by Players
3.1.1 Global Mucopolysaccharidosis Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Mucopolysaccharidosis Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MUCOPOLYSACCHARIDOSIS THERAPEUTICS BY REGIONS
4.1 Mucopolysaccharidosis Therapeutics Market Size by Regions (2018-2023)
4.2 Americas Mucopolysaccharidosis Therapeutics Market Size Growth (2018-2023)
4.3 APAC Mucopolysaccharidosis Therapeutics Market Size Growth (2018-2023)
4.4 Europe Mucopolysaccharidosis Therapeutics Market Size Growth (2018-2023)
4.5 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023)
5.2 Americas Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023)
5.3 Americas Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023)
6.2 APAC Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023)
6.3 APAC Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Mucopolysaccharidosis Therapeutics by Country (2018-2023)
7.2 Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023)
7.3 Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Mucopolysaccharidosis Therapeutics by Region (2018-2023)
8.2 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023)
8.3 Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MUCOPOLYSACCHARIDOSIS THERAPEUTICS MARKET FORECAST
10.1 Global Mucopolysaccharidosis Therapeutics Forecast by Regions (2024-2029)
10.1.1 Global Mucopolysaccharidosis Therapeutics Forecast by Regions (2024-2029)
10.1.2 Americas Mucopolysaccharidosis Therapeutics Forecast
10.1.3 APAC Mucopolysaccharidosis Therapeutics Forecast
10.1.4 Europe Mucopolysaccharidosis Therapeutics Forecast
10.1.5 Middle East & Africa Mucopolysaccharidosis Therapeutics Forecast
10.2 Americas Mucopolysaccharidosis Therapeutics Forecast by Country (2024-2029)
10.2.1 United States Mucopolysaccharidosis Therapeutics Market Forecast
10.2.2 Canada Mucopolysaccharidosis Therapeutics Market Forecast
10.2.3 Mexico Mucopolysaccharidosis Therapeutics Market Forecast
10.2.4 Brazil Mucopolysaccharidosis Therapeutics Market Forecast
10.3 APAC Mucopolysaccharidosis Therapeutics Forecast by Region (2024-2029)
10.3.1 China Mucopolysaccharidosis Therapeutics Market Forecast
10.3.2 Japan Mucopolysaccharidosis Therapeutics Market Forecast
10.3.3 Korea Mucopolysaccharidosis Therapeutics Market Forecast
10.3.4 Southeast Asia Mucopolysaccharidosis Therapeutics Market Forecast
10.3.5 India Mucopolysaccharidosis Therapeutics Market Forecast
10.3.6 Australia Mucopolysaccharidosis Therapeutics Market Forecast
10.4 Europe Mucopolysaccharidosis Therapeutics Forecast by Country (2024-2029)
10.4.1 Germany Mucopolysaccharidosis Therapeutics Market Forecast
10.4.2 France Mucopolysaccharidosis Therapeutics Market Forecast
10.4.3 UK Mucopolysaccharidosis Therapeutics Market Forecast
10.4.4 Italy Mucopolysaccharidosis Therapeutics Market Forecast
10.4.5 Russia Mucopolysaccharidosis Therapeutics Market Forecast
10.5 Middle East & Africa Mucopolysaccharidosis Therapeutics Forecast by Region (2024-2029)
10.5.1 Egypt Mucopolysaccharidosis Therapeutics Market Forecast
10.5.2 South Africa Mucopolysaccharidosis Therapeutics Market Forecast
10.5.3 Israel Mucopolysaccharidosis Therapeutics Market Forecast
10.5.4 Turkey Mucopolysaccharidosis Therapeutics Market Forecast
10.5.5 GCC Countries Mucopolysaccharidosis Therapeutics Market Forecast
10.6 Global Mucopolysaccharidosis Therapeutics Forecast by Type (2024-2029)
10.7 Global Mucopolysaccharidosis Therapeutics Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Shire (Takeda Pharmaceutical Company Limited)
11.1.1 Shire (Takeda Pharmaceutical Company Limited) Company Information
11.1.2 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Offered
11.1.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Shire (Takeda Pharmaceutical Company Limited) Main Business Overview
11.1.5 Shire (Takeda Pharmaceutical Company Limited) Latest Developments
11.2 Denali Therapeutics
11.2.1 Denali Therapeutics Company Information
11.2.2 Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Offered
11.2.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Denali Therapeutics Main Business Overview
11.2.5 Denali Therapeutics Latest Developments
11.3 ArmaGen
11.3.1 ArmaGen Company Information
11.3.2 ArmaGen Mucopolysaccharidosis Therapeutics Product Offered
11.3.3 ArmaGen Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 ArmaGen Main Business Overview
11.3.5 ArmaGen Latest Developments
11.4 REGENXBIO Inc.
11.4.1 REGENXBIO Inc. Company Information
11.4.2 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Offered
11.4.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 REGENXBIO Inc. Main Business Overview
11.4.5 REGENXBIO Inc. Latest Developments
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Information
11.5.2 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Offered
11.5.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Sangamo Therapeutics Main Business Overview
11.5.5 Sangamo Therapeutics Latest Developments
11.6 BioMarin
11.6.1 BioMarin Company Information
11.6.2 BioMarin Mucopolysaccharidosis Therapeutics Product Offered
11.6.3 BioMarin Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 BioMarin Main Business Overview
11.6.5 BioMarin Latest Developments
11.7 Lysogene
11.7.1 Lysogene Company Information
11.7.2 Lysogene Mucopolysaccharidosis Therapeutics Product Offered
11.7.3 Lysogene Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Lysogene Main Business Overview
11.7.5 Lysogene Latest Developments
11.8 Abeona Therapeutics Inc.
11.8.1 Abeona Therapeutics Inc. Company Information
11.8.2 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Offered
11.8.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Abeona Therapeutics Inc. Main Business Overview
11.8.5 Abeona Therapeutics Inc. Latest Developments
11.9 Ultragenyx Pharmaceutical
11.9.1 Ultragenyx Pharmaceutical Company Information
11.9.2 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Offered
11.9.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Ultragenyx Pharmaceutical Main Business Overview
11.9.5 Ultragenyx Pharmaceutical Latest Developments
11.10 Genzyme Corporation
11.10.1 Genzyme Corporation Company Information
11.10.2 Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Offered
11.10.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Genzyme Corporation Main Business Overview
11.10.5 Genzyme Corporation Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Mucopolysaccharidosis Therapeutics Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Intravenous
Table 3. Major Players of Intracerebroventricular (ICV)
Table 4. Mucopolysaccharidosis Therapeutics Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 7. Mucopolysaccharidosis Therapeutics Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 10. Global Mucopolysaccharidosis Therapeutics Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Player (2018-2023)
Table 12. Mucopolysaccharidosis Therapeutics Key Players Head office and Products Offered
Table 13. Mucopolysaccharidosis Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Mucopolysaccharidosis Therapeutics Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Regions (2018-2023)
Table 18. Global Mucopolysaccharidosis Therapeutics Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Mucopolysaccharidosis Therapeutics Market Size Market Share by Country (2018-2023)
Table 22. Americas Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 24. Americas Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 26. APAC Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Region (2018-2023)
Table 28. APAC Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 30. APAC Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 32. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Country (2018-2023)
Table 34. Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 36. Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Mucopolysaccharidosis Therapeutics
Table 45. Key Market Challenges & Risks of Mucopolysaccharidosis Therapeutics
Table 46. Key Industry Trends of Mucopolysaccharidosis Therapeutics
Table 47. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Mucopolysaccharidosis Therapeutics Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Shire (Takeda Pharmaceutical Company Limited) Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 52. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Offered
Table 53. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Shire (Takeda Pharmaceutical Company Limited) Main Business
Table 55. Shire (Takeda Pharmaceutical Company Limited) Latest Developments
Table 56. Denali Therapeutics Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 57. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Offered
Table 58. Denali Therapeutics Main Business
Table 59. Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Denali Therapeutics Latest Developments
Table 61. ArmaGen Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 62. ArmaGen Mucopolysaccharidosis Therapeutics Product Offered
Table 63. ArmaGen Main Business
Table 64. ArmaGen Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. ArmaGen Latest Developments
Table 66. REGENXBIO Inc. Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 67. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Offered
Table 68. REGENXBIO Inc. Main Business
Table 69. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. REGENXBIO Inc. Latest Developments
Table 71. Sangamo Therapeutics Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 72. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Offered
Table 73. Sangamo Therapeutics Main Business
Table 74. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Sangamo Therapeutics Latest Developments
Table 76. BioMarin Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 77. BioMarin Mucopolysaccharidosis Therapeutics Product Offered
Table 78. BioMarin Main Business
Table 79. BioMarin Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. BioMarin Latest Developments
Table 81. Lysogene Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 82. Lysogene Mucopolysaccharidosis Therapeutics Product Offered
Table 83. Lysogene Main Business
Table 84. Lysogene Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Lysogene Latest Developments
Table 86. Abeona Therapeutics Inc. Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 87. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Offered
Table 88. Abeona Therapeutics Inc. Main Business
Table 89. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Abeona Therapeutics Inc. Latest Developments
Table 91. Ultragenyx Pharmaceutical Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 92. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Offered
Table 93. Ultragenyx Pharmaceutical Main Business
Table 94. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Ultragenyx Pharmaceutical Latest Developments
Table 96. Genzyme Corporation Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 97. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Offered
Table 98. Genzyme Corporation Main Business
Table 99. Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Genzyme Corporation Latest Developments
Table 1. Mucopolysaccharidosis Therapeutics Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Intravenous
Table 3. Major Players of Intracerebroventricular (ICV)
Table 4. Mucopolysaccharidosis Therapeutics Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 7. Mucopolysaccharidosis Therapeutics Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 10. Global Mucopolysaccharidosis Therapeutics Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Player (2018-2023)
Table 12. Mucopolysaccharidosis Therapeutics Key Players Head office and Products Offered
Table 13. Mucopolysaccharidosis Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Mucopolysaccharidosis Therapeutics Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Regions (2018-2023)
Table 18. Global Mucopolysaccharidosis Therapeutics Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Mucopolysaccharidosis Therapeutics Market Size Market Share by Country (2018-2023)
Table 22. Americas Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 24. Americas Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 26. APAC Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Region (2018-2023)
Table 28. APAC Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 30. APAC Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 32. Europe Mucopolysaccharidosis Therapeutics Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Country (2018-2023)
Table 34. Europe Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 36. Europe Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Mucopolysaccharidosis Therapeutics
Table 45. Key Market Challenges & Risks of Mucopolysaccharidosis Therapeutics
Table 46. Key Industry Trends of Mucopolysaccharidosis Therapeutics
Table 47. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Mucopolysaccharidosis Therapeutics Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Mucopolysaccharidosis Therapeutics Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Shire (Takeda Pharmaceutical Company Limited) Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 52. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Offered
Table 53. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Shire (Takeda Pharmaceutical Company Limited) Main Business
Table 55. Shire (Takeda Pharmaceutical Company Limited) Latest Developments
Table 56. Denali Therapeutics Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 57. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Offered
Table 58. Denali Therapeutics Main Business
Table 59. Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Denali Therapeutics Latest Developments
Table 61. ArmaGen Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 62. ArmaGen Mucopolysaccharidosis Therapeutics Product Offered
Table 63. ArmaGen Main Business
Table 64. ArmaGen Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. ArmaGen Latest Developments
Table 66. REGENXBIO Inc. Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 67. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Offered
Table 68. REGENXBIO Inc. Main Business
Table 69. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. REGENXBIO Inc. Latest Developments
Table 71. Sangamo Therapeutics Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 72. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Offered
Table 73. Sangamo Therapeutics Main Business
Table 74. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Sangamo Therapeutics Latest Developments
Table 76. BioMarin Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 77. BioMarin Mucopolysaccharidosis Therapeutics Product Offered
Table 78. BioMarin Main Business
Table 79. BioMarin Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. BioMarin Latest Developments
Table 81. Lysogene Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 82. Lysogene Mucopolysaccharidosis Therapeutics Product Offered
Table 83. Lysogene Main Business
Table 84. Lysogene Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Lysogene Latest Developments
Table 86. Abeona Therapeutics Inc. Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 87. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Offered
Table 88. Abeona Therapeutics Inc. Main Business
Table 89. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Abeona Therapeutics Inc. Latest Developments
Table 91. Ultragenyx Pharmaceutical Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 92. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Offered
Table 93. Ultragenyx Pharmaceutical Main Business
Table 94. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Ultragenyx Pharmaceutical Latest Developments
Table 96. Genzyme Corporation Details, Company Type, Mucopolysaccharidosis Therapeutics Area Served and Its Competitors
Table 97. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Offered
Table 98. Genzyme Corporation Main Business
Table 99. Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Genzyme Corporation Latest Developments
LIST OF FIGURES
Figure 1. Mucopolysaccharidosis Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Mucopolysaccharidosis Therapeutics Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Mucopolysaccharidosis Therapeutics Sales Market Share by Country/Region (2022)
Figure 8. Mucopolysaccharidosis Therapeutics Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Type in 2022
Figure 10. Mucopolysaccharidosis Therapeutics in Hospital
Figure 11. Global Mucopolysaccharidosis Therapeutics Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Mucopolysaccharidosis Therapeutics in Clinic
Figure 13. Global Mucopolysaccharidosis Therapeutics Market: Clinic (2018-2023) & ($ Millions)
Figure 14. Mucopolysaccharidosis Therapeutics in Other
Figure 15. Global Mucopolysaccharidosis Therapeutics Market: Other (2018-2023) & ($ Millions)
Figure 16. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Application in 2022
Figure 17. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Player in 2022
Figure 18. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Mucopolysaccharidosis Therapeutics Market Size 2018-2023 ($ Millions)
Figure 20. APAC Mucopolysaccharidosis Therapeutics Market Size 2018-2023 ($ Millions)
Figure 21. Europe Mucopolysaccharidosis Therapeutics Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size 2018-2023 ($ Millions)
Figure 23. Americas Mucopolysaccharidosis Therapeutics Value Market Share by Country in 2022
Figure 24. United States Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Region in 2022
Figure 29. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Type in 2022
Figure 30. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Application in 2022
Figure 31. China Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Country in 2022
Figure 38. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Figure 39. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Figure 40. Germany Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 54. APAC Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 55. Europe Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 57. United States Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 58. Canada Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 61. China Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 62. Japan Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 63. Korea Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 65. India Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 66. Australia Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 67. Germany Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 68. France Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 69. UK Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 70. Italy Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 71. Russia Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 72. Spain Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 75. Israel Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 78. Global Mucopolysaccharidosis Therapeutics Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Mucopolysaccharidosis Therapeutics Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Mucopolysaccharidosis Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Mucopolysaccharidosis Therapeutics Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Mucopolysaccharidosis Therapeutics Sales Market Share by Country/Region (2022)
Figure 8. Mucopolysaccharidosis Therapeutics Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Type in 2022
Figure 10. Mucopolysaccharidosis Therapeutics in Hospital
Figure 11. Global Mucopolysaccharidosis Therapeutics Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Mucopolysaccharidosis Therapeutics in Clinic
Figure 13. Global Mucopolysaccharidosis Therapeutics Market: Clinic (2018-2023) & ($ Millions)
Figure 14. Mucopolysaccharidosis Therapeutics in Other
Figure 15. Global Mucopolysaccharidosis Therapeutics Market: Other (2018-2023) & ($ Millions)
Figure 16. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Application in 2022
Figure 17. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Player in 2022
Figure 18. Global Mucopolysaccharidosis Therapeutics Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Mucopolysaccharidosis Therapeutics Market Size 2018-2023 ($ Millions)
Figure 20. APAC Mucopolysaccharidosis Therapeutics Market Size 2018-2023 ($ Millions)
Figure 21. Europe Mucopolysaccharidosis Therapeutics Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size 2018-2023 ($ Millions)
Figure 23. Americas Mucopolysaccharidosis Therapeutics Value Market Share by Country in 2022
Figure 24. United States Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Region in 2022
Figure 29. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Type in 2022
Figure 30. APAC Mucopolysaccharidosis Therapeutics Market Size Market Share by Application in 2022
Figure 31. China Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Country in 2022
Figure 38. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Figure 39. Europe Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Figure 40. Germany Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Mucopolysaccharidosis Therapeutics Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 54. APAC Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 55. Europe Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 57. United States Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 58. Canada Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 61. China Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 62. Japan Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 63. Korea Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 65. India Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 66. Australia Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 67. Germany Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 68. France Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 69. UK Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 70. Italy Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 71. Russia Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 72. Spain Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 75. Israel Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Mucopolysaccharidosis Therapeutics Market Size 2024-2029 ($ Millions)
Figure 78. Global Mucopolysaccharidosis Therapeutics Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Mucopolysaccharidosis Therapeutics Market Size Market Share Forecast by Application (2024-2029)
